168 related articles for article (PubMed ID: 34288818)
1. Integrated multi-omics analysis of the clinical relevance and potential regulatory mechanisms of splicing factors in hepatocellular carcinoma.
Zhao YJ; Wu LY; Pang JS; Liao W; Chen YJ; He Y; Yang H
Bioengineered; 2021 Dec; 12(1):3978-3992. PubMed ID: 34288818
[TBL] [Abstract][Full Text] [Related]
2. Integrative analysis reveals the prognostic value and functions of splicing factors implicated in hepatocellular carcinoma.
Wang Y; Yang F; Shang J; He H; Yang Q
Sci Rep; 2021 Jul; 11(1):15175. PubMed ID: 34312475
[TBL] [Abstract][Full Text] [Related]
3. Profiles of prognostic alternative splicing signature in hepatocellular carcinoma.
Wu F; Chen Q; Liu C; Duan X; Hu J; Liu J; Cao H; Li W; Li H
Cancer Med; 2020 Mar; 9(6):2171-2180. PubMed ID: 31975560
[TBL] [Abstract][Full Text] [Related]
4. Systematic profiling of a novel prognostic alternative splicing signature in hepatocellular carcinoma.
Zhang D; Duan Y; Wang Z; Lin J
Oncol Rep; 2019 Dec; 42(6):2450-2472. PubMed ID: 31578577
[TBL] [Abstract][Full Text] [Related]
5. Alteration of splicing factors' expression during liver disease progression: impact on hepatocellular carcinoma outcome.
Wang H; Lekbaby B; Fares N; Augustin J; Attout T; Schnuriger A; Cassard AM; Panasyuk G; Perlemuter G; Bieche I; Vacher S; Selves J; Péron JM; Bancel B; Merle P; Kremsdorf D; Hall J; Chemin I; Soussan P
Hepatol Int; 2019 Jul; 13(4):454-467. PubMed ID: 31140152
[TBL] [Abstract][Full Text] [Related]
6. Genome-Wide Profiling of Alternative Splicing Signatures Associated with Prognosis and Immune Microenvironment of Hepatocellular Carcinoma.
Liu Z; Ye J; Khan AA; Chen J; Zhou L; Zheng S; Xu X
Med Sci Monit; 2021 Aug; 27():e930052. PubMed ID: 34407065
[TBL] [Abstract][Full Text] [Related]
7. Identification of prognostic and metastasis-related alternative splicing signatures in hepatocellular carcinoma.
Huang R; Yan G; Sun H; Zhang J; Song D; Kong R; Yan P; Hu P; Xie A; Wang S; Zhuang J; Yin H; Meng T; Huang Z
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32627826
[TBL] [Abstract][Full Text] [Related]
8. Splicing regulator SLU7 preserves survival of hepatocellular carcinoma cells and other solid tumors via oncogenic miR-17-92 cluster expression.
Urtasun R; Elizalde M; Azkona M; Latasa MU; García-Irigoyen O; Uriarte I; Fernández-Barrena MG; Vicent S; Alonso MM; Muntané J; Prieto J; Ávila MA; Berasain C
Oncogene; 2016 Sep; 35(36):4719-29. PubMed ID: 26804174
[TBL] [Abstract][Full Text] [Related]
9. Genome-Wide Analysis of Prognostic Alternative Splicing Signature and Splicing Factors in Lung Adenocarcinoma.
Chang YS; Tu SJ; Chiang HS; Yen JC; Lee YT; Fang HY; Chang JG
Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33142748
[TBL] [Abstract][Full Text] [Related]
10. Prognostic alternative splicing regulatory network of RBM25 in hepatocellular carcinoma.
Zhang YF; Wang YX; Zhang N; Lin ZH; Wang LR; Feng Y; Pan Q; Wang L
Bioengineered; 2021 Dec; 12(1):1202-1211. PubMed ID: 33830865
[TBL] [Abstract][Full Text] [Related]
11. PCBP1 regulates the transcription and alternative splicing of metastasis‑related genes and pathways in hepatocellular carcinoma.
Huang S; Luo K; Jiang L; Zhang XD; Lv YH; Li RF
Sci Rep; 2021 Dec; 11(1):23356. PubMed ID: 34857818
[TBL] [Abstract][Full Text] [Related]
12. Identification of prognostic alternative splicing events related to the immune microenvironment of hepatocellular carcinoma.
Yu S; Cai L; Liu C; Gu R; Cai L; Zhuo L
Mol Med; 2021 Apr; 27(1):36. PubMed ID: 33832428
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of aberrantly expressed methylation‑driven genes in hepatocellular carcinoma: A study based on The Cancer Genome Atlas.
Li J; Chen N; Gong X
Mol Med Rep; 2019 Dec; 20(6):5304-5314. PubMed ID: 31661127
[TBL] [Abstract][Full Text] [Related]
14. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
[TBL] [Abstract][Full Text] [Related]
15. Characterization of alternative splicing events and prognostic signatures in breast cancer.
Han P; Zhu J; Feng G; Wang Z; Ding Y
BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836
[TBL] [Abstract][Full Text] [Related]
16. Alternative splicing events in tumor immune infiltration in renal clear cell carcinomas.
Wang Z; Zhu L; Li K; Sun Y; Giamas G; Stebbing J; Peng L; Yu Z
Cancer Gene Ther; 2022 Oct; 29(10):1418-1428. PubMed ID: 35370291
[TBL] [Abstract][Full Text] [Related]
17. Identification of drug targets and prognosis projection for uterine carcinosarcoma based on alternative splicing events.
Zhang X; Yin X; Zhang L; Ye Z; Liang G
Comput Biol Med; 2023 Jan; 152():106346. PubMed ID: 36470146
[TBL] [Abstract][Full Text] [Related]
18. Comprehensively analysis of splicing factors to construct prognosis prediction classifier in prostate cancer.
Zhang H; Tian J; Ren S; Han B; Tian R; Zuo X; Liu H; Wang Z; Cui Y; Liu L; Guo H; Zhang F; Niu R
J Cell Mol Med; 2023 Sep; 27(18):2684-2700. PubMed ID: 37559353
[TBL] [Abstract][Full Text] [Related]
19. Prognostic index of aberrant mRNA splicing profiling acts as a predictive indicator for hepatocellular carcinoma based on TCGA SpliceSeq data.
Wu HY; Peng ZG; He RQ; Luo B; Ma J; Hu XH; Dang YW; Chen G; Pan SL
Int J Oncol; 2019 Aug; 55(2):425-438. PubMed ID: 31268164
[TBL] [Abstract][Full Text] [Related]
20. Global profiling of alternative RNA splicing events provides insights into molecular differences between various types of hepatocellular carcinoma.
Tremblay MP; Armero VE; Allaire A; Boudreault S; Martenon-Brodeur C; Durand M; Lapointe E; Thibault P; Tremblay-Létourneau M; Perreault JP; Scott MS; Bisaillon M
BMC Genomics; 2016 Aug; 17(1):683. PubMed ID: 27565572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
